GlaxoSmithKline and Innoviva announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta...
GlaxoSmithKline plc and Theravance, Inc. announced that the European Commission has on 18 November 2013, granted marketing authorisation for Relvar...
CHMP recommends change to authorisation for Relvar Ellipta in asthma.
GlaxoSmithKline and Theravance, Inc. have announced that the European Medicines Agency�s (EMA) Committee for Medicinal Products for Human Use (CHMP)...
GlaxoSmithKline and Innoviva announced positive results from the innovative Salford Lung Study (SLS) of Relvar Ellipta (fluticasone furoate/vilanterol) in asthma,...
GlaxoSmithKline plc and Theravance, Inc. announced initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for...
GlaxoSmithKline and Innoviva announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New...
GlaxoSmithKline and Theravance have announced positive results from two Phase III studies, which showed that patients with Chronic Obstructive Pulmonary...
GlaxoSmithKline and Innoviva announced positive headline results from the innovative Salford Lung Study (SLS) in Chronic Obstructive Pulmonary Disease (COPD)....
GlaxoSmithKline and Innoviva announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy...